Pharma & Clinical Research
Fund the Trials. Extend the Runway. Reach Commercialization.
In pharma and clinical research, development cycles are measured in years and capital needs are immense. SR&ED gives Ontario CROs and biotech firms the non-dilutive liquidity to bridge the gap between discovery and commercialization. For every $1M in qualifying clinical salaries, an Ontario CCPC can recover roughly $600,000+ in combined federal and provincial incentives, and as of 2026 lab equipment and capital expenditures are eligible again.
Why It Matters
How SR&ED creates value for pharma & clinical
Extend Your Runway Without Dilution
Refundable SR&ED credits put cash back in your account to reinvest in Phase I-III trials, so you fund the next milestone without giving up equity to bridge a financing round.
Subsidize Your Scientific Talent
Recover roughly 64% of eligible salaries for principal investigators, clinical research associates, formulation scientists, and lab technicians, the people who drive your pipeline forward.
Modernize Your Lab Infrastructure
Capital expenditures are eligible again in 2026. Spectrometers, bioreactors, cold-chain systems, and specialized instrumentation now qualify for credits, letting you upgrade facilities on the government's dime.
Compete as a Global Trial Destination
Stacking the 35% federal credit with Ontario's OITC and ORDTC makes the province one of the most cost-effective jurisdictions on earth to run clinical trials. We help you capture every layer.
2026 Incentives
The credits you can stack
| Incentive | Rate | Detail |
|---|---|---|
| Federal Enhanced ITC | 35% | Refundable on the first $6M of eligible spend, raised from $3M so scaling biotechs stay in the high-refund bracket longer. |
| Ontario Innovation Tax Credit (OITC) | 8% | Refundable for small and medium CCPCs, stacking directly on top of the federal credit for your Ontario R&D spend. |
| Ontario R&D Tax Credit (ORDTC) | 3.5% | Non-refundable credit that offsets your Ontario corporate tax, adding further value to qualifying clinical research expenditures. |
recovered per $1M in qualifying clinical salaries for an Ontario CCPC
Eligibility
What qualifies in pharma & clinical
If your team is resolving genuine technological uncertainty, this work likely counts. Here's what we typically see qualify.
Protocol & Trial Design Innovation
Developing novel clinical trial designs, adaptive protocols, or patient stratification methods where no established guidelines exist and the outcome is genuinely uncertain.
Drug Delivery & Formulation
Experimental work on bioavailability, stability, controlled release, or novel delivery mechanisms that requires systematic testing and analysis to resolve technological uncertainty.
Phase I-III Clinical Trials
Systematic testing to prove safety and efficacy qualifies when the work seeks to advance medical and scientific knowledge, not just satisfy a regulatory checkbox.
Bioinformatics & Computational Biology
Building custom algorithms to analyze genomic data, model pharmacokinetics, or predict drug-target interactions where existing tools cannot solve the problem.
Process & Manufacturing Scale-Up
Developing or refining synthesis routes, assay methods, and GMP-aligned manufacturing processes where translating bench results to production introduces real experimental risk.
What Our Clients Say
Results in Pharma & Clinical
Research and innovation are at the core of our business, but navigating government funding programs can be overwhelming. Innovotis understood our science, our challenges, and our vision. They translated complex R&D activities into a compelling SR&ED claim and identified additional funding that accelerated our growth. Their expertise allowed us to focus on what matters most, improving patient outcomes.